Hydrogen sulfide is a novel regulator implicated in glucocorticoids-inhibited bone formation

Jun Ma,Changgui Shi,Zhongyang Liu,Bin Han,Lei Guo,Lei Zhu,Tianwen Ye
DOI: https://doi.org/10.18632/aging.102269
2019-09-16
Aging
Abstract:Glucocorticoids contribute to the increased incidence of secondary osteoporosis. Hydrogen sulfide (H<sub>2</sub>S) is a gasotransmitter and plays an essential role in bone metabolism. In this study, we investigated the therapeutic effects of H<sub>2</sub>S on glucocorticoid-induced osteoporosis (GIO). We found that dexamethasone (Dex) decreased serum H<sub>2</sub>S and two key H<sub>2</sub>S-generating enzymes in the bone marrow <i>in vivo</i>, cystathione b-synthase and cystathione g-lyase. Treatment of H<sub>2</sub>S-donor GYY4137 in rat significantly relieved the inhibitory effect of Dex on bone formation. Dex inhibited osteoblasts proliferation and osteogenic differentiation and decreased the expressions of the two H<sub>2</sub>S-generating enzymes. Further investigation showed that H<sub>2</sub>S was involved in Dex-mediated osteoblasts proliferation, differentiation, and apoptosis. Mechanistically, GYY4137 promoted osteoblastogenesis by activating Wnt signaling through increased production of the Wnt ligands. In comparison, the blockage of Wnt/β-catenin signaling pathway significantly alleviated the effect of H<sub>2</sub>S on osteoblasts. In conclusion, the restoration of H<sub>2</sub>S levels is a potential novel therapeutic approach for GIO.
What problem does this paper attempt to address?